Pioneering the next generation of treatment solutions
We support innovation across the continuum of care, to help to develop new technologies, treatments and vaccines.
-
The new Ebola clinical trial that’s focused on helping halt future outbreaks
A groundbreaking partnership between countries, health organizations and companies worldwide—including Johnson & Johnson—hopes to find the most promising vaccines to help protect people from the virus.
Featured stories
-
-
Meet the Johnson & Johnson Scientist Who’s Helping to Fight Tropical Diseases in His Homeland
Two decades after leaving India, Anil Koul has returned to helm its Institute of Microbial Technology. For Dengue Awareness Month, we caught up with him to learn how he’s hoping to combat this tropical scourge and another disease that kills over a million worldwide.
-
Janssen Wins Prestigious International Prix Galien Award for MDR-TB Treatment
Ground breaking therapy offers hope for people with Multi-Drug Resistant Tuberculosis (MDR-TB) -
How Johnson & Johnson is helping save children around the world from intestinal worm infections
For the fifth anniversary of the London Declaration, we’re sharing the steps the company has taken to fulfill its promise to fight neglected tropical diseases—including the development of a chewable form of mebendazole.
More from Johnson & Johnson
-
Striving for a cure for multiple myeloma: What HCPs need to know
Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer. -
The future of immunology
Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body. -
What is IL-23?
This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat immune-mediated diseases such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.
